font size
Sign in

CAPITAL MARKETS:

AbbVie Terminates Shire Acquisition, But M&A Activity Remains Brisk

Total life sciences transactions through first 10 months of 2014 reach $253.3 Billion, says Burrill Media


New tax rules from the U.S. Department of the Treasury intended to discourage so-called inversions to avoid U.S. taxation led to the termination of AbbVie’s planned $54.7 billion acquisition of Shire, but it did little to slow the robust M&A activity that has characterized the current year, Burrill Media reported. Read More
Todays Stories
Podcast Therapeutic Vaccine for Parkinson's Disease Shows Early Promise

Kuldip Dave, director of research programs for the Michael J. Fox Foundation, discusses encouraging early-stage results for Affiris' experimental therapeutic vaccine for Parkinson's, what the results tell us, and why alpha-synuclein may be a compelling target in the fight against Parkinson’s disease.

By the numbers Pharmas Tap Academia for Drug Discovery



Non-traditional partnering deals have become the norm over the past few years as Big Pharma has shifted its resources away from internal R&D to outsourcing innovation. Such was the case over the past week as Bristol-Myers Squibb and Astellas Pharma partnered to access biopharmaceutical innovation coming out of academia and research institutes.